# Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease

> **NCT04031729** · PHASE1,PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 80 (actual)

## Conditions studied

- Nonalcoholic Fatty Liver
- Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** Aspirin 81 mg
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04031729
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-12
- **Primary completion:** 2023-02-23
- **Final completion:** 2023-02-23
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2024-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04031729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04031729, "Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04031729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*